文献速递免疫规划传染病防控与疫情报告

肌内注射疫苗佐剂纳米乳与CpG的新型组合可诱导有效的抗甲型流感病毒免疫应答

A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus.
PubMed 文献 · Vaccine · 2020-03-31

研究开发了适用于肌内注射的纳米乳佐剂NE02,单独或联合CpG在小鼠和雪貂中评估重组H5(rH5)免疫应答。rH5-NE02肌内注射显著增加rH5特异性IgG,在雪貂病毒挑战中提供完全保护和无菌免疫;NE02联合CpG加速抗体应答并产生协同NF-kB激活效应,在雪貂挑战后HAI和VN血清转化分别至少达75%和88%,并改善体温稳定和体重下降。

要点

  • 肌内注射rH5-NE02显著增加rH5特异性IgG,雪貂病毒挑战中提供完全保护和无菌免疫。
  • NE02联合CpG加速抗体应答,伴IFN-γ和IL-17升高及IL-5下调,协同激活NF-kB。
  • 雪貂挑战后rH5-NE02+CpG肌内注射HAI和VN血清转化分别至少75%和88%,优于单用NE02。

核心结论

  • 肌内注射NE02佐剂化rH5可诱导针对H5抗原的强而广的免疫应答,并有效保护动物免受致死性H5挑战。
  • 将该佐剂与CpG联合可增强免疫应答并改善雪貂病毒挑战结局,结果提示佐剂组合可能有助于增强H5免疫应答和改善流感感染保护。

研究设计与样本

  • 开发了适用于肌内注射的新型纳米乳佐剂NE02,在小鼠和雪貂模型中单独或联合CpG评估H5免疫应答。
  • 评估指标包括血清IgG及IgG亚类、支气管肺泡灌洗液IgA、细胞因子和NF-kB激活分析。
  • 疫苗效力通过血凝抑制(HAI)、病毒中和(VN)试验及雪貂病毒挑战评估。

主要发现

  • 肌内注射rH5-NE02显著增加rH5特异性IgG,雪貂病毒挑战中提供完全保护和无菌免疫,所有受试动物均获保护。
  • NE02联合CpG产生加速的抗体应答,伴IFN-γ和IL-17应答升高及IL-5下调,并对NF-kB激活产生协同效应。
  • 免疫雪貂病毒挑战后,rH5-NE02+CpG肌内注射HAI和VN抗体应答血清转化分别至少75%和88%,并较单用NE02改善体温稳定和体重下降。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination is the most effective approach to prevent infection with highly pathogenic avian influenza (HPAI). Adjuvants are often used to induce effective immune responses and overcome the immunological weakness of recombinant HPAI antigens. Given the logistical challenges of immunization to HPAI during pandemic situations, vaccines administered via the intramuscular (I.M.) route would be of value. METHODS: A new formulation of nanoemulsion adjuvant (NE02) suitable for I.M. vaccination was developed. This NE02 was evaluated alone and in combination with CpG to develop H5 immune responses in mouse and ferret models. Measures of recombinant H5 (rH5) specific immunity evaluated included serum IgG and IgG subclasses, bronchoalveolar lavage fluid IgA, and cytokines. The activation of NF-kB was also analyzed. The efficacy of the vaccine was assessed by performing hemagglutination inhibition (HAI), virus neutralization (VN) assays, and viral challenges in ferrets. RESULTS: I.M. vaccination with rH5-NE02 significantly increased rH5-specific IgG and protected ferrets in the viral challenge model providing complete protection and sterile immunity in all animals tested. Combining NE02 and CpG produced accelerated antibody responses and this was accompanied by an elevation of IFN-γ and IL-17 responses and the downregulation of IL-5. The combination also caused a synergistic effect on NF-kB activation. In immunized ferrets after viral challenge, the rH5-NE02 + CpG vaccine via I.M. achieved at least 75% and 88% seroconversion of HAI and VN antibody responses, respectively, and improved body temperature stabilization and weight loss over NE02 alone. CONCLUSIONS: The I.M. injection of NE02 adjuvanted rH5 elicits strong and broad immune responses against H5 antigens and effectively protects animals from lethal H5 challenge. Combining this adjuvant with CpG enhanced immune responses and provided improvements in outcomes to viral challenge in ferrets. The results suggest that combinations of adjuvants may be useful to enhance H5 immune responses and improve protection against influenza infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang SH, Chen J, Smith D, et al. A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus. Vaccine. 2020. PMID: 32245642. doi:10.1016/j.vaccine.2020.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。